Vir Biotechnology, Inc. Net Income 2017–2025
Vir Biotechnology, Inc. reported $-437.99M of net income for fiscal 2025. That was 16.1% higher than fiscal 2024. Compared with fiscal 2020, the change was -46.6%.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $-437.99M | -638.9% | +16.1% |
| FY 2024 | $-521.96M | -703.4% | +15.1% |
| FY 2023 | $-615.06M | -713.7% | -219.2% |
| FY 2022 | $515.84M | 31.9% | -2.4% |
| FY 2021 | $528.58M | 48.3% | +277.0% |
| FY 2020 | $-298.67M | -391.1% | -71.0% |
| FY 2019 | $-174.68M | -2159.0% | -50.7% |
| FY 2018 | $-115.88M | -1086.3% | -65.9% |
| FY 2017 | $-69.85M | -2579.5% | — |
Source: Vir Biotechnology, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open VIR 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Vir Biotechnology, Inc. reported $-437.99M of net income for fiscal 2025. That was 16.1% higher than fiscal 2024. Compared with fiscal 2020, the change was -46.6%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Vir Biotechnology, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeVir Biotechnology, Inc. — frequently asked questions
What is Vir Biotechnology, Inc.'s net income?
Vir Biotechnology, Inc. (VIR) reported net income of $-437.99M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Vir Biotechnology, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.